Trials / Completed
CompletedNCT03819127
Vildagliptin in Older Adults With Diabetes and Mild Cognitive Impairment
Effects of Vildagliptin, a DPP-4 Inhibitor, in Elderly Diabetic Patients With Mild Cognitive Impairment
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 60 (actual)
- Sponsor
- University of Catania · Academic / Other
- Sex
- All
- Age
- 65 Years
- Healthy volunteers
- Not accepted
Summary
This study investigates the effect of vildagliptin, an inhibitor of the enzyme DPP-4, on the cognitive functioning of elderly diabetic patients with mild cognitive impairment (MCI) documented at mini mental state examination (MMSE). In this prospective study, 60 diabetic elderly people were enrolled and divided according to their glycated hemoglobin (HbA1c) values in 2 groups: Group A, (HbA1c \<7.5%, n=30) treated with metformin, and Group B (HbA1c \>7.5%, n=30) treated with metformin plus vildagliptin. We evaluated MMSE, fasting plasma glucose (FPG) and HbA1c at baseline and after 24 weeks treatment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Vildagliptin 50 MG Oral Tablet | |
| DRUG | Metformin Pill |
Timeline
- Start date
- 2015-01-01
- Primary completion
- 2016-09-01
- Completion
- 2016-09-01
- First posted
- 2019-01-28
- Last updated
- 2019-01-28
Source: ClinicalTrials.gov record NCT03819127. Inclusion in this directory is not an endorsement.